Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles.
We present a case of multiple primary lung cancer(MPLC) displaying heterogeneous EGFR and PTEN molecular profiles. Considering the physical condition of patients, the patient underwent surgical resection of the right lung lesion displaying gefitinib-insensitive and continued gefitinib treatment for the gefitinib-sensitive lesions in the left lung. As far as we know, this is the first report documenting a case of an integrated therapy strategy using surgical resection with gefitinib treatment for MPLC displaying different EGFR and PTEN molecular profiles. The patient has been in progression free survival up to now. Our experience could provide a treatment strategy for patients with similar disease.
Department of Thoracic Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zhouyu
Z
Zhu
Department of Thoracic Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Tao
T
Yu
Department of Thoracic Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Ying
Y
Chai
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D001706:Biopsy; D017024:Chemotherapy, Adjuvant; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics*; D000077156:Gefitinib; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009378:Neoplasms, Multiple Primary / Q000201:enzymology / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D051059:PTEN Phosphohydrolase / Q000235:genetics*; D010641:Phenotype; D011013:Pneumonectomy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D000077156:Gefitinib
EGFR; PTEN; gefitinib; multiple primary lung cancer